Scorpius Holdings Inc. · OTC:SCPX
Scorpius — IPO Roadshow (March 2024)
19 slides from Scorpius's IPO roadshow presentation, Mar 7, 2024
Slide 1: Issuer Free Writing Prospectus
Issuer Free Writing Prospectus Filed pursuant to Rule 433 Registration no 333-251255 March 7, 2024
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . In some cases, these forward - looking statements can be identified by the use of forward - looking terminology,
Slide 3: Offering information and prospectus notice
This presentation highlights basic information about us and the proposed offering. Because it is a summary, it does not contain all of the information that you should consider before investing. We have filed a registration statement (including a prospectus supplement and the accompanying prospectus)
Slide 4: Forward-looking statements
This presentation includes statements that are, or may be deemed, “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended . In some cases, these forward - looking statements can be identified by the use of forward - looking terminology,
Slide 5: Investment Highlights
Investment Highlights » Pure - play biologics CDMO offering a comprehensive range of services from process and analytical development through clinical - stage and small - scale commercial cGMP manufacturing » Growing demand for Contract Development & Manufacturing Organization (CDMO) services and si
Slide 6: Leadership Team
Leadership Team Joe Payne President and Chief Operating Officer 20+ Years Of Experience Alcami, Tergus, Teva Brian O’Mara VP, Process Sciences 20+ Years Of Experience Ambrx, Bristol - Myers Squibb, Genencor, Wyeth Stephan Kutzer Senior Advisor 25+ Years Of Experience Alcami, Lonza Matt LeClair VP, M
Slide 7: Growing Market Due to Rising Demand and Expanding Treatment Scope
Scorpius is positioned to take advantage of rapid growth of the biopharmaceutical market now with a rising demand for biologics and the aging global population *Precedence Research, Global Biologics Market, July 2023 Growing Market Due to Rising Demand and Expanding Treatment Scope 6 What Are Biopha
Slide 8: Why the CDMO Market is Experiencing Growth
CDMOs generate a perfect partnership opportunity with biopharmaceutical companies , as the CDMOs function as a hedge against intensive capital investment and a dynamic demand curve 7 Timeline (Yrs.) Reference Biopharmaceutical Development Biosimilar Development CDMOs are less expensive and may take
Slide 9: Large Molecule Drug Substance CDMO Market Growth
Large Molecule Drug Substance CDMO Market size is poised to grow from $10.86B in 2022 to $21B by 2030, growing at a CAGR of 8.6% in the forecast period (2023 - 2030)* *SkyQuest Large Molecule Industry Forecast, July 2023 Over the last decade, R&D spending has steadily shifted from its focus on small
Slide 10: Business History
Nov ’20: Scorpius BioManufacturing is founded Aug ’21: Broke ground on San Antonio, TX facility Q4 ’22: Onboarded first client for microbial commercial contract Oct ’22: Opened San Antonio facility 2H ‘21 1H ‘22 2H ‘22 1H ‘23 2H ‘23 2H ‘20 1H ‘21 In the two years since breaking ground, Scorpius is c
Slide 11: Manufacturing Snapshot
Clinical - scale biomanufacturing in San Antonio, TX located in the heart of a thriving innovation district Highly skilled scientific and manufacturing leadership team U.S. - sourced supply chain with US and international customers In - house process development and analytical services including mic
Slide 12: Supported Drug Modalities
11 Supported Drug Modalities Mammalian Cell Culture • Antibody Production • Monoclonals, Bi - Specifics • Recombinant Therapeutic Proteins • Allogeneic and Autologous Cell Therapy • Fc Fusions • Cells, Exosomes, Secretome Microbial Fermentation • Recombinant Therapeutic Proteins & Enzyme Products •
Slide 13: Preliminary Q4 results and key highlights
» Approx. $65M in total expenditures developing Scorpius’ CDMO business since inception, including approx. $32M of direct facility investment (PP&E, etc.). » Preliminary estimates for Q4 revenue of approx. $3.4M - $3.6M, nearly all of which is from our CDMO business, demonstrating execution of custo
Slide 14: Balance Sheet and Capitalization Table
As of September 30, 2023 Balance Sheet $2,042,741 Cash and Cash Equivalents 24,180,163 Total Current Assets 69,915,144 Total Assets 24,487,847 Total Current Liabilities 36,468,500 Total Liabilities 33,446,644 Stockholders’ Equity As of March 5, 2024 Capitalization Table 26,031,964 Common Stock 5,727
Slide 15: 2024 Goals
2024 Goals » Deliver seamless execution on signed manufacturing contracts » Expand pipeline with target biotech, pharma, and research customers » Streamline operations to deliver at scale » Bolster and strengthen in - house development and analytical services » Develop talent and culture, creating a
Slide 16: Summary
Summary 15 » Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical - scale manufacturing capacity within the industry » Scorpius began 2023 with $3M of signed manufacturing contracts, which has grown to over $21M in signed
Slide 17: Media and Investor Relations Contact
Media and Investor Relations Contact David Waldman ir@scorpiusbiologics.com 16
Slide 18: Media and Investor Relations Contact
Media and Investor Relations Contact David Waldman ir@scorpiusbiologics.com 16
Slide 19: Financial Results from Discontinued Operations
18 Source: Company SEC filings Financial Results from Discontinued Operations